Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With Human Immunodeficiency Virus Type 1: First Results From the ANRS-MIE CARLAPOP Study

Journal:

Clinical Infectious Diseases

Published:

2025-08-18

DOI:

10.1093/cid/ciaf385

Affiliations:

17

Authors:

16

Go to article

Institutions	Authors	Share
Emerging Viral Diseases Unit (UVE), France	3.000000	0.19
SINERGIES Laboratory, France	2.000000	0.13
Institut de Recherche en Santé, Environnement et Travail (IRSET), France	2.000000	0.13
Bichat-Claude Bernard Hospital, France	1.000000	0.06
Infection, Antimicrobials, Modelling, Evolution (IAME), France	1.000000	0.06
Bordeaux Population Health (BPH), France	1.000000	0.06
Lyon University Hospital (HCL), France	1.000000	0.06
Centre d’Investigation Clinique de Poitiers (CIC de Poitiers), France	1.000000	0.06
Pierre Louis Institute of Epidemiology and Public Health (iPLESP), France	1.000000	0.06
University Hospital Nantes (CHU de Nantes), France	0.500000	0.03
Targets and Drugs for Infectious Diseases and Cancer (IICiMED), France	0.500000	0.03
Innovations Thérapeutiques et Résistances (InTheRes), France	0.500000	0.03
Toulouse University Hospital (CHU-Toulouse), France	0.500000	0.03
CHU Nice, France	0.333333	0.02
Laboratoire Jean-Alexandre Dieudonné (LJAD), France	0.333333	0.02
National Institute for Research in Computer Science and Control (INRIA), France	0.333333	0.02

Interested in Clinical Sciences?